Home › Myelodysplastic Syndromes › California
Myelodysplastic Syndromes clinical trials in California
41 studies for Myelodysplastic Syndromes are looking for participants at sites in California.
Cities in California
- Baldwin Park26 studies
- Los Angeles10 studies
- Mountain View9 studies
- Orange7 studies
- San Francisco6 studies
- Irvine5 studies
- Sacramento3 studies
- San Diego3 studies
- Fresno3 studies
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
- Kaiser Permanente Dublin, Dublin
- Kaiser Permanente-Fremont, Fremont
- Kaiser Permanente Fresno Orchard Plaza, Fresno
- and 21 more
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT05564390Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia
- City of Hope - Duarte, Duarte
- City of Hope - Lennar, Irvine
- UCLA, Los Angeles
- and 1 more
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 23, 2026 · NCT05320198Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial)
- UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine
- UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT06577441A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions
- City of Hope - Comprehensive Cancer Center (CCC), Duarte
- Providence Medical Group, Santa Rosa
- Cancer & Blood Research Center, Whittier
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 18, 2026 · NCT07422480Phase 1 Study of AUTX-703 in Relapsed/Refractory AML and MDS
- City of Hope National Medical Center, Duarte
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 14, 2026 · NCT06846606The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
- Kaiser Permanente Downey Medical Center, Downey
- Loma Linda University Medical Center, Loma Linda
- Miller Children's and Women's Hospital Long Beach, Long Beach
- and 8 more
RecruitingPhase 1/2
Up to age 22 · All sexes · Updated Aug 25, 2026 · NCT04726241A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS)
- City of Hope National Medical Center, Duarte
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Aug 21, 2026 · NCT04419649A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions
- City of Hope, Duarte
- Los Angeles Cancer Network, Glendale
- UC San Diego Moores Cancer Center, La Jolla
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Aug 21, 2026 · NCT06499285Study of QUAIL-100 in Pediatric and Young Adult Participants With High-Risk Hematologic Malignancies Who Have Received a Hematopoietic Stem Cell Transplantation
- Lucille Packard Children's Hospital of Stanford University, Palo Alto
RecruitingPhase 1
18 Months – 39 Years · All sexes · Updated Aug 21, 2026 · NCT07573111Total Marrow and Lymphoid Irradiation in Combination With Fludarabine and Melphalan as Conditioning for Allogeneic Peripheral Blood Stem Cell Hematopoietic Cell Transplant in Older Patients With Refractory and Relapsed Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome
- City of Hope Medical Center, Duarte
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Aug 20, 2026 · NCT07582172ICP-248 in Combination With Azacitidine for the Treatment in Patients With Myeloid Malignancies
- Chao Family Comprehensive Cancer Center, University of California, Irvine, Orange
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 18, 2026 · NCT06656494TACrolimus Targeted Immunosuppression Cessation in ALlogeneic HCT
- Stanford University, Palo Alto
RecruitingPhase 1
Ages 18 to 80 · All sexes · Updated Aug 17, 2026 · NCT07302776Study of R289 in Patients With Lower-risk Myelodysplastic Syndromes (LR MDS)
- University of California, Los Angeles, Los Angeles
- University of California, Irvine, Orange
- Stanford Cancer Institute, Palo Alto
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Aug 10, 2026 · NCT05308264225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody With Fludarabine, Melphalan and Total Marrow and Lymphoid Irradiation as Conditioning Treatment for Donor Stem Cell Transplant in Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome
- City of Hope Medical Center, Duarte
RecruitingPhase 1
Ages 18 to 70 · All sexes · Updated Jul 31, 2026 · NCT06287944A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant
- City of Hope Medical Center, Duarte
RecruitingPhase 1Healthy volunteers welcome
Ages 18 to 75 · All sexes · Updated Jul 28, 2026 · NCT07020533Tagraxofusp and Azacitidine for Maintenance Treatment in Patients With CD123 Positive AML and MDS Following Donor Hematopoietic Cell Transplant
- City of Hope Medical Center, Duarte
RecruitingPhase 1
Ages 18 to 75 · All sexes · Updated Jul 16, 2026 · NCT06498973Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
- UCLA Department of Medicine, Los Angeles
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Jul 7, 2026 · NCT07216443A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
- City of Hope, Duarte
- UC Davis, Sacramento
- Stanford Health Care, Stanford
RecruitingPhase 1
Ages 12 to 78 · All sexes · Updated Jul 1, 2026 · NCT03802695Emapalumab With Post-Transplant Cyclophosphamide, Tacrolimus and Mycophenolate Mofetil for the Prevention of Graft-versus-Host Disease After Donor Reduced-Intensity Hematopoietic Cell Transplant
- City of Hope Medical Center, Duarte
RecruitingPhase 1
Ages 18 to 75 · All sexes · Updated Jul 1, 2026 · NCT06996119Vedolizumab Plus Post-transplant Cyclophosphamide and Short Course Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation After Reduced Intensity Conditioning
- City of Hope Medical Center, Duarte
RecruitingPhase 2
Ages 18 to 80 · All sexes · Updated Jun 29, 2026 · NCT06815003Trial for Patients w/ Advanced Hematologic Malignancies Undergoing Allogeneic HCT
- Stanford University, Palo Alto
RecruitingPhase 1
Ages 18 to 70 · All sexes · Updated Jun 23, 2026 · NCT06551584SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
- City of Hope, Duarte
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jun 17, 2026 · NCT03113643A Study of Momelotinib in Participants With Low-risk Myelodysplastic Syndrome
- GSK Investigational Site, Duarte
- GSK Investigational Site, Irvine
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Jun 2, 2026 · NCT06847867A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
- Keck School of Medicine of USC, Los Angeles
- UC Irvine Health - Chao Family Comprehensive Cancer Center, Orange
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Apr 30, 2026 · NCT04256317Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults With Cancer
- Beckman Research Institute of City of Hope, Duarte
- VA Medical Center, Fresno, Fresno
- Santa Clara Valley Medical Center, Fruitdale
- and 5 more
Recruiting
Ages 18 and older · All sexes · Updated Apr 30, 2026 · NCT05297734Orca-T Following Chemotherapy and Total Marrow and Lymphoid Irradiation for the Treatment of Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia or Myelodysplastic Syndrome
- City of Hope Medical Center, Duarte
RecruitingPhase 1Healthy volunteers welcome
Ages 60 and older · All sexes · Updated Apr 29, 2026 · NCT06195891A Study of GLB-001 in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher Risk Myelodysplastic Syndromes
- City of Hope Medical Center, Duarte
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Apr 13, 2026 · NCT06146257Curcumin to Improve Inflammation and Symptoms in Patients With Clonal Cytopenia of Undetermined Significance, Low Risk Myelodysplastic Syndrome, and Myeloproliferative Neoplasms
- Los Angeles General Medical Center, Los Angeles
- USC / Norris Comprehensive Cancer Center, Los Angeles
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Mar 27, 2026 · NCT06063486A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
- Hoag Family Cancer Center, Newport Beach
- Stanford University, Palo Alto
RecruitingPhase 1/2
Ages 12 and older · All sexes · Updated Mar 24, 2026 · NCT04988555Venetoclax Basket Trial for High Risk Hematologic Malignancies
- University of California San Francisco-Benioff Children's Hospital, San Francisco
RecruitingPhase 1
Ages 1 to 40 · All sexes · Updated Mar 12, 2026 · NCT05292664CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant
- City of Hope Medical Center, Duarte
RecruitingPhase 2Healthy volunteers welcome
Ages 18 to 75 · All sexes · Updated Mar 10, 2026 · NCT06059391Olutasidenib for the Treatment of Patients With IDH1 Mutated AML, MDS or CMML After Donor Hematopoietic Cell Transplant
- City of Hope Medical Center, Duarte
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Mar 5, 2026 · NCT06543381CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
- UCLA, Los Angeles
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jan 16, 2026 · NCT05143996Metabolically Optimized, Non-cytotoxic Low Dose Weekly Decitabine/Venetoclax in MDS and AML
- University of California Davis Health (UC Davis Health), Sacramento
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Jan 5, 2026 · NCT05184842Exercise Training and NR Supplementation Trial to Improve Fitness in AYA HCT Survivors
- City of Hope Medical Center, Duarte
RecruitingPhase 2
Ages 10 to 30 · All sexes · Updated Dec 4, 2025 · NCT05194397Ruxolitinib With Tacrolimus and Methotrexate for the Prevention of Graft Versus Host Disease in Pediatric and Young Adult Patients Undergoing Allogeneic Hematopoietic Cell Transplant for Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome
- City of Hope Medical Center, Duarte
RecruitingPhase 2
Ages 2 to 22 · All sexes · Updated Oct 31, 2025 · NCT06128070SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Duarte
- Massive Bio SYNERGY-AI site, Irvine
- Massive Bio SYNERGY-AI site, La Jolla
- and 3 more
RecruitingObservational study
All ages · All sexes · Updated Oct 28, 2025 · NCT03452774A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome
- City of Hope Medical Center, Duarte
- University of California Los Angeles, Los Angeles
- Stanford Cancer Center, Palo Alto
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 24, 2025 · NCT06501196Study of REM-422 in Patients With AML or Higher Risk MDS
- City of Hope, Duarte
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Apr 23, 2025 · NCT06297941Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT)
- City of Hope, Duarte
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Apr 15, 2025 · NCT06462365From ClinicalTrials.gov, data retrieved Sep 29, 2026. Each study sets its own eligibility; the study team decides who can join.